Transforming PTSD Treatment Through Psychedelic Innovation
At OctaGenix®, we are pioneering the responsible development of psychedelics as next-generation therapeutics. Our research focuses on unlocking the potential of compounds such as Ibogaine, Psilocybin, DMT, and MDMA to address some of the most urgent and underserved needs in mental health and neurology.
Conventional treatments for PTSD, Depression, Anxiety, and Addiction often fall short due to; limited efficacy, poor patient adherence, and heavy side-effect burdens which remain barriers to full and long-term recovery.
In July 2025, OctaGenix and DioMEDe Science announced a joint program (Ibg-P001-DSO) to develop and commercialise the world’s first clinically validated microdosed ibogaine treatment for PTSD and related conditions.
“This partnership is a testament to our shared commitment to innovation and patient well-being.” – Dr. Zulfiqar Khan, CEO, OctaGenix
- Safety and tolerability: Sub-perceptual dosing minimises cardiovascular and psychoactive risks.
- Neuroplasticity and repair: Modulation of NMDA receptors and upregulation of BDNF/GDNF supports brain rewiring and trauma recovery.
- Trauma processing: Facilitates fear extinction and memory reconsolidation without overwhelming psychedelic effects.
- Improved compliance: Gentle, sustained dosing integrates well with psychotherapy, enhancing long-term outcomes.
- Preclinical studies: Pharmacology, pharmacokinetics, and toxicology demonstrating safety and efficacy.
- Phase 1 trials: Safety, tolerability, and pharmacokinetics in healthy volunteers.
- Phase 2 trials: Randomised, placebo-controlled clinical studies in PTSD patients.
- Phase 3 pivotal trials: Multicentre, global studies measuring durability of response, functional outcomes, and quality of life improvements.
Our goal is to deliver the first approved prescription psychedelic therapy for PTSD, establishing a new global standard in mental health care.
While Ibogaine is our flagship programme, we are actively developing research frameworks for additional compounds:
- Psilocybin – Investigating therapeutic potential in treatment-resistant depression, end-of-life anxiety, and alcohol use disorder.
- DMT – Exploring ultra-rapid-acting antidepressant properties and its role in neurological repair and consciousness reset mechanisms.
- MDMA – Advancing research into complex PTSD and social anxiety disorders, building on promising global clinical trial data.
Each programme reflects our philosophy: science-driven innovation, patient-centred care, and uncompromising regulatory compliance.
- Global need: Over 8.3 million US adults live with PTSD, and 40% show resistance to current therapies.
- Scientific breakthrough: Psychedelics uniquely promote neuroplasticity, emotional reset, and trauma memory reconsolidation, effects conventional drugs cannot replicate.
- Economic impact: The psychedelic therapeutics market is projected to exceed $10 billion globally within the decade.
Strategic advantage: OctaGenix® combines AI-driven clinical design, in-house UK GMP manufacturing, and proven regulatory expertise, accelerating the path from discovery to licensed therapy.
- All trials will be conducted under Good Clinical Practice (GCP) and overseen by ethical review boards.
- Manufacturing is managed in-house in the UK, ensuring full quality control and intellectual property protection.
- We engage patients, clinicians, and regulators at every stage to ensure therapies are effective, affordable, and accessible.
Our leadership team has deep expertise in transforming early insights landmark therapies.
The success story of Sativex® in the medical cannabis sector demonstrated how foresight, patient need, and scientific rigour can reshape global healthcare. Psychedelics represent the next wave of this transformation, and OctaGenix® is positioned to lead.
Frequently Asked Questions
Everything You Need to Know About Microdosed Ibogaine
Ibogaine is a naturally occurring alkaloid derived from the African shrub Tabernanthe iboga. At high doses, it produces intense psychedelic experiences, but at low microdoses, it can modulate brain pathways without hallucinogenic effects.
Traditional ibogaine treatments involve a single, high dose, often accompanied by hallucinations and potential cardiovascular risks. Microdosed ibogaine delivers chronic, low doses that avoid these effects while still promoting neuroplasticity, emotional regulation, and trauma processing.
Our initial focus is on:
Post-Traumatic Stress Disorder (PTSD)
Complex PTSD (cPTSD)
Treatment-Resistant Depression (TRD)
These conditions affect millions worldwide and often fail to respond to current standard therapies.
Manufacturing and formulation will be conducted in-house in the UK, under MHRA-aligned protocols, ensuring quality, scalability, and IP protection across all stages (R&D, GLP, GMP).
Preclinical – GLP studies in safety, pharmacology, and toxicology.
Phase 1 – 30–50 healthy volunteers to establish safe dosing and tolerability.
Phase 2 – Randomized, placebo-controlled PTSD trials (80–150 patients per arm).
Phase 3 – Multicenter pivotal studies (6–12 months, larger populations).
Microdosed ibogaine acts on multiple systems:
NMDA receptors → enhances neuroplasticity
BDNF & GDNF upregulation → supports neuronal growth and repair
Serotonin & dopamine modulation → stabilizes mood regulation
Default Mode Network modulation → reduces rumination and hypervigilance
Yes, that is the foundation of our program. By focusing on low, sub-perceptual dosing, the therapy avoids the intense psychoactive and cardiovascular risks linked to traditional ibogaine use. Extensive preclinical toxicology and pharmacokinetics studies will confirm safety before clinical trials.
Preclinical – GLP studies in safety, pharmacology, and toxicology.
Phase 1 – 30–50 healthy volunteers to establish safe dosing and tolerability.
Phase 2 – Randomized, placebo-controlled PTSD trials (80–150 patients per arm).
Phase 3 – Multicenter pivotal studies (6–12 months, larger populations).
The global PTSD therapeutics market is growing rapidly. With 8.3M US adults affected annually and up to 40% resistant to first-line therapies, there is a significant unmet need. Microdosed ibogaine is positioned to address this gap, with first-mover advantage in next-generation psychedelic medicine.
We welcome discussions with institutional investors, strategic partners, and research collaborators.
📧 Contact us at: biz@octagenix.com
📞 Or schedule a call via our [Investor Relations page]
Safer approach: microdosing avoids hallucinogenic burdens
Integration with psychotherapy: designed as an adjunct, not a replacement
Scientific leadership: track record includes the development of Sativex, which created multi-billion-dollar returns for early investors
Partnership strength: joint program with DioMEDe Science and the Wyatt Group (USA)
